Diabetes in rural towns: effectiveness of continuing education and feedback for healthcare providers in altering diabetes outcomes at a population level: protocol for a cluster randomised controlled trial by Christine L Paul et al.
Implementation
Science
Paul et al. Implementation Science 2013, 8:30
http://www.implementationscience.com/content/8/1/30STUDY PROTOCOL Open AccessDiabetes in rural towns: effectiveness of
continuing education and feedback for
healthcare providers in altering diabetes
outcomes at a population level: protocol for a
cluster randomised controlled trial
Christine L Paul1,2*, Leon Piterman3, Jonathan Shaw4, Catherine Kirby3, Robert W Sanson-Fisher1,2,
Mariko L Carey1,2, Jennifer Robinson1,2, Patrick McElduff1,2 and Isaraporn Thepwongsa3Abstract
Background: Type 2 diabetes is one of the fastest growing chronic diseases internationally. The health
complications associated with type 2 diabetes can be prevented, delayed, or improved via early diagnosis and
effective management. This research aims to examine the impact of a primarily web-based educational intervention
on the diabetes care provided by general practitioners (GPs) in rural areas, and subsequent patient outcomes. A
population-level approach to outcome assessment is used, via whole-town de-identified pathology records.
Methods/design: The study uses a cluster randomised controlled trial with rural communities as the unit of
analysis. Towns from four Australian states were selected and matched on factors including rurality, population size,
proportion of the population who were Indigenous Australians, and socio-economic status. Eleven pairs of towns
from two states were suitable for the trial, and one town from each pair was randomised to the experimental
group. GPs in the towns allocated to the experimental group are offered an intervention package comprising
education on best practice diabetes care via an on-line active learning module, a moderated discussion forum,
access to targeted and specialist advice through an on-line request form, and town-based performance feedback
on diabetes monitoring and outcomes. The package is offered via repeated direct mail.
Discussion: The benefits of the outcomes of the trial are described along with the challenges and limitations
associated with the methodology.
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Type 2 diabetes is one of the fastest growing chronic
diseases internationally [1]. It is estimated that world
prevalence of diabetes in adults will rise from 6.4% in
2010 to 7.7% by 2030 [2]. Long-term complications asso-
ciated with diabetes include macrovascular disease, cor-
onary heart disease, stroke, retinopathy, and kidney
diseases [3]. Those diagnosed with diabetes have double
the risk of developing cardiovascular disease (CVD) and
have a higher mortality due to their first CVD event
[3,4]. Diabetic nephropathy affects approximately 10% of
people with diabetes, is the most common cause of end-
stage kidney disease, and diabetes is a major contributor
to lower limb amputations and visual loss [3]. The direct
and indirect costs of diabetes and its associated compli-
cations to the health system and to individuals is sub-
stantial [5].
The health complications associated with type 2 dia-
betes can be prevented, delayed, or lessened if diabetes
is diagnosed early and is well controlled. While there are
many factors important to diabetes control, metabolic
markers of poor diabetes control such as elevated blood
glucose, blood lipids, cholesterol, and urinary albumin
indicate increased risk of diabetic complications [6-11].
Interventions designed to impact on multiple risk factors
in people with diabetes can reduce risk of diabetes com-
plications [6,12]. However, achieving optimal diabetes
management at a population-level remains challenging.
General practitioners (GPs), or primary care physi-
cians, play a major role in diabetes management [3]. In
an effort to improve diabetes management, national
Clinical Practice Guidelines for general practice specify
the requirements for testing of blood lipids, HbA1c, and
urinary albumin [6,13]. Target levels for each of these
metabolic indicators are provided, and follow-up care is
recommended if results fall outside these parameters
[13]. While these metabolic markers cannot assess the
quality of an individual’s diabetes care, they represent
key objective measures of the management of diabetes at
a population level. While there were about 818,000 Aus-
tralians diagnosed with diabetes in 2009 and 2010, it ap-
pears that a minority have received the recommended
annual testing of metabolic markers [14].
In Australia, people living in regional, rural, and re-
mote regions have mortality rates between 10% and 70%
higher than those living in the major cities [15]. Rural
and remote communities are of particular importance
because rates of diabetes consultations are higher than
in other areas of Australia [16]. Rates of diabetes-related
hospitalisation rise with increasing remoteness of resi-
dence [3], as do death rates due to diabetes [3]. The pro-
portion of diabetic patients meeting targets for total
cholesterol, triglycerides, and blood pressure levels is
also lower in rural areas compared with urban areas[17]. The role of the GP is critical in rural settings, be-
cause there may be less access to specialist services. In
Australia, organisations such as the Rural Health Educa-
tion Foundation run distance education programs, in-
cluding internet-based programs for rural GPs; however,
these have not been evaluated for effect on quality of
care or patient outcomes.
Continuing medical education (CME) is a commonly
employed mechanism to improve clinical practice [17].
There is growing evidence that CME approaches that in-
volve multiple exposures to educational material over time
and a variety of educational techniques are effective at
improving doctors’ knowledge, attitudes, and patient out-
comes [18]. Web-based CME is increasing in popularity
and is of particular relevance to GPs in non-metropolitan
locations where face-to-face training opportunities are less
accessible. However, while some studies have examined
the effect of CME on participant satisfaction [19], few
have examined the effect on patient outcomes, and none
at the population level.
Studies that examine the effect of provider-change
strategies on patient outcomes have done so by looking
at patients linked to providers who have participated in
the study [20-22]. The outcomes at the patient level,
therefore, do not include the patients of providers who
choose not to participate, patients who are ‘missed’ or
excluded by their provider, patients who do not provide
consent, and providers or patients lost to follow-up.
While these methodological flaws are often unavoidable,
they severely limit the generalisability of the results. This
project will use objective data to examine uptake and ef-
fectiveness of CME and additional intervention strat-
egies at the population level in the rural setting. To
meet this objective, the research design uses communi-
ties as the unit of analysis and administrative data sets
(whole town de-identified pathology data) without the
usual problems of generalisability resulting from enrol-
ling practices and patients.
In addition to drawing on best evidence for CME [18]
the intervention will be multifaceted; including an on-line
Active Learning Module (ALM) attracting CME points,
and strategies designed to improve adherence to guideline
recommendations such as performance feedback [23,24].
Non-metropolitan GPs are likely to be receptive to the
web-based aspects of our proposed approach because
computer use by GPs in rural and remote areas is higher
than that of GPs in metropolitan areas [16]. Rural towns
also offer a greater chance of capturing the whole popula-
tion than does a selected group of GPs.
Aims and objectives
Objective
To test whether population-level improvements can be
achieved by implementing evidence-based practice
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betes in rural communities.
Primary aim
To test whether a rural GP-focused intervention involv-
ing Continuing Medical Education (CME), reminders
and feedback can improve clinical outcomes as mea-
sured by glycaemic control.
Secondary aims
To examine whether the above-mentioned intervention
can:
1. Improve patterns of diabetes care as measured by
whether the frequency of testing for hemoglobin
A1c, blood lipids and urinary albumin meets
NHMRC (National Health and Medical Research
Council) guidelines.
2. Improve other clinical outcomes as measured by
blood lipid control and urinary albumin control.
Method/design
Study design
The study uses a cluster randomised controlled trial with
towns as the unit of allocation and analysis. This enables
the impact of the interventions to be examined at a
population level and allowed the outcomes related to
diabetes care for individuals to be examined regardless
of whether care was sought from one or multiple
GPs within their community. Randomisation by town
may result in similar intervention effects even if patients
change GPs within their town over the course of
the study. Towns were randomised via a computer-
generated stratified randomisation scheme in SAS (Stat-
istical Analysis Software). Allocation remained concealed
to all participants and all those assessing outcomes
throughout the study. Because the clusters were towns,
consent was not required from clusters or members of
clusters. Management of the various challenges associ-
ated with this design is addressed in the discussion.
Selection and matching of town sample
Towns were defined by postal area and matched to town
names through the Australia Post website. Towns were
eligible for selection if they: had an ‘Australian Remote-
ness Index for Areas Plus’ (ARIA+) [25] classification of
2.0 or greater; had a population of 10,000 to 30,000
people; were in the Australian states of Victoria, New
South Wales (NSW), or Queensland, i.e., where the two
collaborating pathology companies operate with good
coverage of regional and rural towns; and had five or
more full-time equivalent GPs according to the Medical
Directory of Australia and cross-matched with census
data. This criterion was included to ensure GP andpatient anonymity. This process identified a possible
43 towns.
Towns were matched in pairs within each state on
the above variables, proportion of population identified
as Indigenous, and socio-economic status (SES). Indi-
genous population was incorporated in the matching
process because the prevalence of diabetes is higher
among Indigenous Australians than in the general popu-
lation [26]. SES using the Socio-Economic Index for
Areas (SEIFA) was also included in the matching process
because diabetes was two to two-and-a-half times more
prevalent among those in the lowest versus the highest
socioeconomic group [26]. The town matching process
was as follows: Towns were sorted by total population,
and pairs selected within each state which were the most
similar; priority was given to average ARIA+, then total
population, followed by Indigenous population (although
for instances of a large difference in indigenous popula-
tion between two towns, general population was of less
importance), and then SEIFA, because all towns had
similar SEIFA codes. Once towns had been divided into
pairs (NSW = 7 pairs, Queensland = 6 pairs, Victoria = 2
pairs), they were ranked according to the ‘best’ pairs. A
minimum distance of 100 km between paired towns was
required to prevent contamination between experimen-
tal and control communities. An initial matching process
incorporating all of the above criteria for inclusion, ex-
clusion, matching, and contamination prevention indi-
cated that there were 17 potentially matched pairs of
towns (i.e., 34 towns). The pathology laboratories operat-
ing in each of the 34 towns were verified via discussion
with pathology providers and searching of the electronic
yellow pages to identify any towns where the two collab-
orating pathology laboratories provided a low proportion
of the pathology services. This excluded a further six
pairs of towns, leaving 11 matched pairs of towns, all of
which were in NSW and Queensland. One town from
each matched pair was randomly allocated to the inter-
vention group and the other to the control group. As in-
dicated in the sample size section, a minimum of seven
matched pairs (14 towns) will be required at follow-up.
Given the possibility that pathology laboratory presence
in a selected town may change over the course of
the study with the result that one or more towns may
become ineligible, all 11 town pairs were included in
the study.
Selection of case sample
For the two-year baseline period, the two pathology
companies used the postcode of the treating doctor to
identify the potential cases in each study town. The ex-
istence of at least one HbA1c test was the criterion for
an individual to be identified as a potential case of dia-
betes. A study case was defined by having either a single
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HbA1c tests within the study period. This approach was
used to exclude those cases where a single HbA1c test
had been used to screen for diabetes. This criterion may
have resulted in the omission of some cases of diabetes
(i.e., people with diabetes who had not had an HbA1c
test). However, more serious forms of bias are avoided,
because neither provider consent nor patient consent
was required.
Data extraction procedure
For each case the following de-identified unit record
data were extracted from pathology laboratory records:
date of birth, gender, de-identified doctor code, postcode
of doctor’s clinic, postcode of patient, date and value of
each HbA1c test, date and value of each cholesterol test,
date and value of each triglycerides test, date of each
HDL cholesterol test, date and value of each LDL chol-
esterol test, and date of each urinary albumin test. The
unit record data were extracted for three time periods:
pre-test measures were taken over the 24 months prior
to the intervention retrospectively; during the interven-
tion, measures were collected prospectively; post-test
measures will be taken in the 24 months following the
termination of the intervention. Where both pathology
companies operate in the same town, the two separate




Glycaemic control The incidence and progression of
complications of diabetes are reduced for people with
lower HbA1c [8-10]. Therefore, guidelines recommend
an overall target of ≤7.0% for HbA1c [6]. Using the most
recent HbA1c for each case within each 24-month
timeframe, the mean HbA1c across the town, and the
proportion of all cases whose most recent HbA1c value
is ≤7.0%, was determined.
Secondary outcome
Frequency of HbA1c testing NHMRC guidelines [6]
recommended HbA1c testing every six months if the re-
sult was <7.0%, with re-testing to occur within three
months if the result was ≥7.0%. Over each 24-month
period, the number of all cases where there was at least
one gap between tests of more than six months (seven
months or greater) was determined and aggregated for
each town. For each case with at least one HbA1c test
>7.0%, the number of cases where a subsequent gap be-
tween HbA1c tests of more than three months (four
months or greater) was determined and aggregated for
each town. The mean gap between HbA1c tests for each
case was also determined.Frequency of blood lipid and urinary albumin testing
Clinical practice guidelines recommended that blood
lipids and urinary albumin levels were tested once every
12 months as part of an annual cycle of care, with re-
testing to occur within three months if the result was
outside recommended levels [13]. Over each 24-month
period, the number of all cases where there was at least
one gap between tests of more than 12 months (13
months or greater) was determined and aggregated for
each town. For each case with at least one test outside
recommended target levels [13], the number of cases
where a subsequent gap between tests of more than
three months (four months or greater) was determined
and aggregated for each town. The mean gap between
blood lipid and urinary albumin tests for each case was
also determined.
Blood lipids and urinary albumin control The follow-
ing targets were recommended for blood lipids: total chol-
esterol <4.0mmol/L; triglycerides <1.5mmol/ L; HDL
cholesterol >1.0 mmol/L; LDL cholesterol <2.5mmol/ L
[13]. A urinary albumin excretion of <20 μg/min is con-
sidered normal [13]. Using the most recent results for
each case within each 24-month timeframe, the mean
values of blood lipids and urinary albumin and the pro-
portion of all cases whose most recent values are within
the relevant target ranges was determined.
Process measures The uptake and implementation of
the intervention were monitored in terms of: number of
GPs who commence and complete the on-line ALM (de-
scribed below); number and type of interactions on the
discussion forum; and number and content of requests
to the diabetes specialist via the on-line request form
(described below). GPs who registered for the ALM were
also invited to complete on-line surveys at pre-test and
post-test regarding self-reported knowledge, attitudes,
awareness of need for change (pre-test), intended
changes in practice (immediate post-test) or actual
changes in practice (follow-up). The surveys consisted of
multiple choice, yes-no, and open-ended questions.
Intervention group Systematic reviews identified sev-
eral CME approaches that were more effective than
others. These included: use of multimedia rather than
single media; use of multiple educational techniques
(e.g., case based learning, discussion groups, personal re-
flection or audit); more than one exposure to the educa-
tional material [18]; and opportunities for practice [27].
GPs in towns allocated to this group were offered an
intervention package comprising several features: CME
on best practice diabetes care via an on-line ALM, in-
cluding a moderated discussion forum, self-audit and
pre-post ALM reflection exercise, access to specialist
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performance feedback on diabetes monitoring and out-
comes. The package was offered via repeated direct mail
using evidence-based strategies, including primer post-
cards, personalised mail, CME or quality improvement
(QI) and Continuing Professional Development (CPD)
points, reminder gifts (jellybeans and tent calendars with
reminder messages), faxed reminders, and an incentive
of $200 for ALM completion [28-32]. The content
addressed the full range of best-practice care, not solely
monitoring metabolic markers, was pilot-tested and
drew on the expertise of the Monash Department of
General Practice and the Baker IDI Heart and Diabetes
Institute. The intervention is to be conducted over two
years and designed to not only provide GPs with pre-
requisite knowledge for optimal primary care manage-
ment of diabetes, but to provide opportunities to
practice and refine skills in the practice setting. The
intervention components are:
1. On-line active learning module (ALM): This
component of the intervention targeted GPs’
knowledge of diabetes care as a necessary but not
sufficient factor for practice change. Because
multimedia education is more effective than a single
medium [18], the ALM included a range of features
and presentation types including: evidence-based
Australian clinical guidelines, video demonstrations,
case studies, knowledge-based quizzes, clinical audit,
self-reflection activities, and a moderated peer
discussion forum. The ALM comprised
approximately six hours of learning activity, for
which GPs received CPD points via their
professional body. Content for the ALM was
developed in consultation with rural GPs and
diabetes specialists to ensure accuracy and relevance
to the rural GP population. The online ALM was
trialled by a small sample of GPs and diabetes
specialists to ensure that the final program was user-
friendly, accurate, and relevant to GPs.
2. Access to specialist advice: Because rural GPs may
not have access to a diabetes specialist in their town,
every mailing to promote the ALM also promoted
the availability of an on-line request form for
specialist advice regarding diabetes, accessed by
secure log in. A diabetes specialist was assigned to
manage queries from GPs in the intervention towns.
This enabled GPs to access advice on applying the
diabetes management principles learned in the
educational program in their day-to-day practice,
and to ask for advice on more complex cases that
arose. Importantly, this represents a mechanism for
case-based learning, which has been demonstrated
to be one of the most promising forms of CME [18].3. Provision of town-based performance feedback: GPs
were provided with town-based feedback which
contained de-identified information about the
proportion of diabetic patients in the town receiving
testing at the recommended frequency and within
target guidelines for HbA1c and blood lipids.
Systematic reviews show that audit and feedback
can have modest effects on changing provider
practice [24].
4. Provision of comparative feedback: GPs were
provided with a summary of the range of
performance per GP in their town. This takes the
form of a graph showing the proportion of patients
per GP who meet guidelines for test frequency and
management (meeting HbA1c targets). Comparative
feedback has been shown to be an effective means of
changing surgeons’ behavior [33,34]. Both forms of
feedback were derived from de-identified data
provided by local pathology laboratories.
Control group No interventions by the research team
are being provided to this group. There ae no restric-
tions on GPs’ access to other available forms of diabetes
information and education opportunities during the
period of the study.
Sample size Assuming that 50% of subjects will be con-
trolled in the usual-care group (i.e., have a HbA1c level
below 7%) and that an absolute increase of 10% is im-
portant (i.e., an increase to 60% in the intervention
group) then, assuming no cluster effect, the study would
require 408 subjects per treatment arm to have 80%
power of detecting a 10% difference at the 5% signifi-
cance level. However with 14 clusters, an average of 464
diabetic patients within each cluster and an estimated
intraclass correlation associated with the outcome of
0.015, the design effect of this study will be 7.9, and
therefore a total of 6,490 subjects will be required. As-
suming each of the 14 towns has an average of 20,000
persons and an average rate of being treated for diabetes
of 2.9%, there would a total of 8,120 subjects with dia-
betes in the study.
Statistical methods Changes in the proportion of pa-
tients in each town exhibiting glycaemic control, appro-
priate frequency of testing for each of HbA1c, blood
lipids, urinary albumin, and control of lipids and albu-
min will be assessed at baseline and post-test as de-
scribed in the measures section. Analysis of the
predictors of metabolic control, using age and gender
will also be assessed. Analyses using cluster-level sum-
maries are more robust than analyses based on
individual-level data when there are fewer than 15 clus-
ters per treatment arm [35]. Therefore, the primary
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the proportion of subjects with a HbA1c level below 7%
within each cluster and then comparing the proportion
of the intervention group with the proportion of the
control group using a two sample t-test. The main ana-
lysis will be conducted with all the available data using
the intention-to-treat principle. Subgroup analyses will
be conducted by gender and age group. A similar ap-
proach will be used to test the secondary outcomes.
Trial status The study has ethical approval from the Hu-
man Research Ethics Committees of Monash University and
the University of Newcastle. The trial has been registered as
a trial at the Australian New Zealand Clinical Trials Registry
(ANZCTR) registration number ACTRN 12611000553976
at www.ANZCTR.org.au/ACTRN12611000553976.aspx. To
date, the baseline measurement phase of the trial has
been completed and the intervention phase is nearing
completion.
Discussion
The study methodology will deliver a community-level
estimate of the effectiveness of a practice-change inter-
vention for diabetes, providing valuable information re-
garding the implementation of large-scale strategies for
practice change.
Challenges and limitations
There were a number of challenges to consider in the
execution and analysis of this type of study. Below is a
description of some of the major challenges and how
they were managed.
Definition of a type 2 diabetes ‘case’
A study case was defined as having either a single
HbA1c test where the result was greater than 7%, or two
HbA1c tests within the study period. This approach was
used to exclude those cases where a single HbA1c test
had been used to screen for diabetes. While this criter-
ion resulted in the omission of some cases of diabetes
(i.e., those who had not had an HbA1c test), the scale of
the study and avoidance of participant bias was consid-
ered to compensate for any potential impact on
generalizability of results. Some individuals may travel,
receiving their care from specialists outside the selected
communities. However, any such effect is likely to be
similar across experimental and control communities.
Use of the HbA1c test as a screening tool
The HbA1c test was not recommended as a screening
test in Australia at the time of study commencement
and does not attract Medicare reimbursement when
used as a diagnostic test. Individuals with only one
HbA1c test where the test result is below 7% will beexcluded from the sample. Therefore, should the use
of the HbA1c test as a screening tool have increased
during the study period, it is unlikely to influence the
study outcome. Should such a change occur, it will be
possible to assess using interrupted time series analysis
whether an overall increase in the use of one-off HbA1c
tests has occurred over time, because the study data on
HbA1c testing will provide a near-complete record of all
HbA1c testing in the study communities over the five-
year study period.
Variation in pathology assay techniques and
instrumentation
HbA1c analysis results are subject to variation as a result
of the type of equipment used, with the analysis method
accounting for differences of up to 23% in the result
[36,37]. In the course of this study, changes in the equip-
ment and methods used for HbA1c analysis were moni-
tored via communication with the two pathology
companies to assess the need for sensitivity analyses ex-
ploring the size of any such effect.
Variation between guidelines on HbA1c test frequency
Both the NHMRC and Royal Australian College of Gen-
eral Practitioners (RACGP) have guidelines on diabetes
management. The NHMRC is the national body that
provides authoritative, evidence-based national guide-
lines on a wide range of health matters. The RACGP
guidelines are designed specifically for the general prac-
tice setting and are available in a handbook along with a
full range of matters relevant to general practice. The
NHMRC guidelines stated that HbA1c testing should
occur every six months [38]. While the RACGP guide-
lines nominated six-month testing of HbA1c, the docu-
ment had a focus on the 12-month cycle of care and the
associated government funding for annual testing [13].
While the ALM and the feedback to GPs focused on the
six-month interval, it is possible that GPs may have
placed more weight on the 12-month interval. There-
fore, analyses will address both six-month and 12-month
intervals for HbA1c testing.
Pathology testing occurring outside the participating
pathology companies or towns
Although considerable efforts have been made to include
only towns where the two participating pathology com-
panies provided the vast majority of pathology services,
it is possible that in some towns a small proportion of
pathology testing may have occurred at other locations.
For example, some pathology testing may have been sent
to hospitals in larger towns nearby. At regular intervals
during the course of the study, a sample of GPs were
asked by telephone where they sent their pathology in
order to assess whether this was occurring. It was also
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to other towns for testing.Matching and merging records for de-identified patient
data across pathology companies
The two pathology companies independently provided
de-identified unit record data for each ‘case’. Therefore,
the data was obtained as two independent data sets that
were merged to provide a profile for all individuals in
each town. Gender and date of birth were used to iden-
tify any individual who may occur in both datasets and
data was merged for that individual.Individuals may move into or out of the dataset over
time due to death, geographical re-location, or initial
diagnosis
The data were analysed on the assumption that individ-
uals entering or leaving a town would occur at a reason-
ably constant rate in each town. These effects would be
expected in equal proportions across the intervention
and control towns.Standard population guidelines may not be appropriate
for all cases
Higher cut-off points for glycaemic control (e.g., 8% for
HbA1c in older patients) may be recommended in some
cases. The primary outcome analysis relates to changes
in mean HcA1c levels and would, therefore, be relatively
unaffected by this factor. Analyses relating to the pro-
portion of cases in each town achieving glycaemic con-
trol may require analyses to apply varying cut points
with respect to age, however this does introduce an add-
itional element of arbitrariness with respect to which age
cut-offs are used.Pathology testing data provides a limited indicator of
quality of diabetes care
The breadth and depth of best-practice diabetes care
cannot be measured by focusing solely on pathology-
based tests. There are a number of aspects of quality
diabetes care, which although important, cannot be mea-
sured within the scope and focus of this studyParticipation rates
Poor participation rates are common in GP research
[39,40]. The study will implement a range of evidence-
based strategies to increase participation. It should be
noted that because the outcome measures are popula-
tion based, even if participation is poor, the study will
provide a ‘real world’ indication of the impact of these
sorts of methods, given that the intervention compo-
nents reflect best practice in CME.Conclusions
Despite the identified methodological challenges, the
study data are likely to provide valuable information re-
garding monitoring and improvement of healthcare
using ongoing administrative data sets at a population
level. The study also has potentially wide-reaching appli-
cations for evaluating guideline adoption free from bias
associated with provider and participant non-consent.
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